$IDXX

IDEXX Laboratories (IDXX), a global leader in animal health diagnostics, reported Q2 2026 revenue of $1.22B (up 9.7% YoY) and EPS of $4.07 (up 15.3%). The company raised its full-year outlook. Analysts have a 'Moderate Buy' consensus, with a mean price target of $718.14, suggesting 30.6% upside. IDXX stock is down 14.2% over 52 weeks, underperforming the S&P 500 and healthcare sector.

IDEXX Laboratories (IDXX) is expanding global commercial capabilities to support CAG Diagnostics recurring revenue growth. The company's software ecosystem is a key value driver. Challenges include third-party distribution and foreign exchange movements. IDXX stock has fallen 13.7% over the past year, despite beating earnings estimates for four consecutive quarters. The company expects a 70-basis-point drag on revenue growth due to currency movements in Q3 2026.

IDEXX Laboratories (IDXX) reported Q2 earnings of $4.27 per share, beating estimates. Revenue rose 10% to $1.22B. The company raised its 2026 EPS outlook to $14.69-$14.94. Growth was driven by diagnostics, while U.S. veterinary traffic remained soft. Operating margin expanded to 35%.

IDEXX Laboratories launched the Catalyst proBNP Test, a cardiac assay for cats and dogs, expanding its diagnostics portfolio. The test targets a $4B global market and integrates with VetConnect PLUS, potentially boosting consumables growth. IDEXX projects $5.7B revenue and $1.5B earnings by 2029, requiring 8.7% annual growth. Analysts' optimism hinges on recurring revenue despite risks like U.S. visit trends and competition.

IDEXX (IDXX) reported Q2 2026 results and an earnings call transcript. Premium instrument placements topped 5,200 units, including about 1,600 inVue Dx analyzers. Q2 EPS was $4.27. IDEXX raised full-year revenue guidance to $4,700 million to $4,745 million and EPS to $14.69 to $14.94, citing recurring revenue growth and margin expansion.

Idexx Laboratories (Nasdaq: IDXX) announced the Catalyst proBNP Test, an in-clinic NT-proBNP assay for both cats and dogs, integrated with its Catalyst point-of-care platform and VetConnect PLUS. The company says it targets a cardiac biomarker used for screening, diagnosis, and monitoring, with availability in North America starting October 2026.

IDEXX (NASDAQ:IDXX) highlighted Q2 results and product updates on its earnings call. VetLab consumables rose 14% organically, Global Reference Laboratory revenue grew over 10% organically, and Rapid Assay revenue returned to growth. IDEXX placed 5,265 premium instruments, including 1,602 inVue Dx analyzers, and raised 2026 revenue outlook to $4.70-$4.745B and EPS to $14.69-$14.94.

Investing.com reports IDEXX Laboratories shares rose 3.9% in pre-open after Q2 2026 results beat expectations. Adjusted EPS was $4.27 vs $3.96 consensus, and revenue was $1.22B vs $1.20B. The company raised and narrowed FY2026 guidance to EPS $14.69-$14.94 and revenue $4.70-$4.75B. U.S. equity futures were also higher.

IDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong volume-driven CAG Diagnostics recurring revenue g

Bank of America said animal health stocks face continued 2Q26 pressure from fewer veterinary visits and higher drug competition. It kept Elanco Animal Health (Elanco) as its top pick with a buy rating, while maintaining neutral ratings on Zoetis and Idexx Laboratories. VetSource data showed Q2 visits down 1.9% YoY and July down 4% YoY. BofA expects FY2026 visits to fall about 2% and sees Elanco pricing rising below Zoetis.